Attached files
| file | filename |
|---|---|
| EX-4.4 - EX-4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES E - Apellis Pharmaceuticals, Inc. | apls-ex44_92.htm |
| EX-32.1 - EX-32.1 - Apellis Pharmaceuticals, Inc. | apls-ex321_8.htm |
| EX-31.2 - EX-31.2 - Apellis Pharmaceuticals, Inc. | apls-ex312_11.htm |
| EX-31.1 - EX-31.1 - Apellis Pharmaceuticals, Inc. | apls-ex311_7.htm |
| EX-23.2 - EX-23.2 CONSENT OF EY - Apellis Pharmaceuticals, Inc. | apls-ex232_147.htm |
| EX-23.1 - EX-23.1 - Apellis Pharmaceuticals, Inc. | apls-ex231_10.htm |
| EX-21.1 - EX-21.1 - Apellis Pharmaceuticals, Inc. | apls-ex211_9.htm |
| 10-K - 10-K - Apellis Pharmaceuticals, Inc. | apls-10k_20191231.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Apellis Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Timothy Sullivan, Chief Financial Officer and Treasurer of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: February 27, 2020 |
|
By: |
/s/ Timothy E. Sullivan |
|
|
|
|
Timothy E. Sullivan |
|
|
|
|
Chief Financial Officer and Treasurer |